Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of navenibart in hereditary angioedema
NL-OMON59717Phase 3Recruiting
- Sponsor
- Astria Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of navenibart in hereditary angioedema (HAE), sponsored by Astria Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Mar 2026; status: recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON59717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59717.